Tromsø, Norway, April 9, 2024 - ArcticZymes Technologies ASA (OSE: AZT) and the
Austrian Centre of Industrial Biotechnology (acib) enters a joint research
project to uncover the benefits of salt active nucleases in purification of
bionanoparticles (BNP's).

ArcticZymes Technologies (AZT) has initiated a collaborative research project
with the Austrian Centre of Industrial Biotechnology (acib), a globally
recognized research center headquartered in Graz, Austria, specializing in
industrial biotechnology. Acib has established itself as a leading contributor
to scientific advancements in the production and purification of
Bionanoparticles (BNPs) utilized in various medical applications including cell
and gene therapy, vaccines, and oncolytic treatment.

AZT's salt-active nucleases have demonstrated significant efficacy in enhancing
the removal of unwanted DNA from BNPs due to their adaptability to relevant
conditions. Through this joint project, AZT and acib will unite their respective
expertise in enzymology and BNPs' production and purification to devise
innovative methodologies aimed at enhancing their purity and scalability. The
project's anticipated outcomes include comprehensive scientific documentation,
which will be disseminated at prominent scientific congresses.

Acknowledging the project's potential impact on human health, the COMET
(Competence Centers for Excellent Technologies) program has allocated funding
(EUR 100.000) to support this collaborative research initiative. COMET fosters
synergies between academic and industrial researchers, facilitating
translational research and innovation in the biotechnology sector.

CEO Michael B. Akoh comments:

"The collaboration with experts in the production and purification of
bionanoparticles is crucial for effectively showcasing the true advantages of
our SAN portfolio. With their extensive publication record in this specialized
field, acib has proven to be the perfect partner for this project.

The acknowledgment and financial support from the COMET program serve to
emphasize the significance and scientific merit of our collaborative project.
This collaboration underscores our commitment to advancing bioprocessing
technologies and improving the efficiency of bionanoparticles purification
methods."

Acib CEO Mathias Drexler comments:

Biotechnology, and especially research on bionanoparticles, is one of the most
promising areas in the quest for better health for all. To achieve a progress
towards the efficient production of these innovative modalities, fruitful
collaborations such as the joint research project together with ArcticZymes
Technologies (AZT) are critical to the development of improved methods and
potential new applications that will have a critical impact in a variety of
fields."

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh          Tel: +46 (0) 70 262 37 15

Email: ir@arcticzymes.com

Austrian Centre of Industrial Biotechnology (acib)

Email: info@acib.at

Website: www.acib.at

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who develop therapeutics, in
vitro diagnostics, and molecular research kit products. Our mission is to make
our customers lives easier by unlocking new solutions to enhance quality of life
and create a more sustainable healthy world.

About the Austrian Centre of Industrial Biotechnology (acib):

The Austrian Centre of Industrial Biotechnology (acib) is an internationally
renowned research center dedicated to advancing industrial biotechnology. With
headquarters, Austria, acib collaborates with academic and industrial partners
worldwide to drive innovation in bioprocessing and biopharmaceutical
development.